The two most common regulatory frameworks for cell therapy starting material — Good Tissue Practice and Good Manufacturing Practice — are not interchangeable. They apply at different development phases, impose different documentation and facility requirements, and have different FDA enforcement postures. Sponsors who conflate them or make supply chain decisions without understanding the distinction between them often discover the gap at IND filing, when fixing it is expensive and time-consuming.
This guide explains what GTP and GMP each require, when each applies, what the transition between them looks like in practice, and how to select starting material suppliers whose regulatory capability matches your program’s current and future needs.
Good Tissue Practice (GTP): 21 CFR 1271 Subpart D
Good Tissue Practice is the regulatory standard established under 21 CFR 1271 for establishments that process human cells, tissues, and cellular and tissue-based products (HCT/Ps). GTP applies to organizations that recover, process, store, label, package, or distribute HCT/Ps, including leukapheresis processing facilities.
GTP requirements cover:
- Facilities and environmental controls. Processing facilities must be designed to prevent contamination and cross-contamination, with appropriate environmental monitoring and controlled access.
- Equipment. Equipment must be appropriately qualified, maintained, and calibrated, with documented records.
- Standard operating procedures. All processing steps must be covered by documented, version-controlled SOPs.
- Donor eligibility determination. Under 21 CFR 1271.50-85, establishments must determine donor eligibility based on communicable disease screening and testing before release of HCT/P for clinical use.
- Processing and process controls. Processing steps must be performed consistently per validated procedures, with deviation management for out-of-specification events.
- Labeling. Labels must include required information including donor identification, product type, intended use designation, and applicable warnings.
- Storage and distribution. Conditions must be appropriate for the product type with documented chain-of-custody.
- Adverse reaction reporting. Reports of adverse reactions related to HCT/P use must be documented and submitted to FDA.
- Inspections. FDA has authority to inspect GTP establishments; inspections are typically conducted on a risk-based schedule.
GTP is the minimum regulatory standard for cell therapy starting material suppliers operating in the research and early clinical phases. A supplier who processes leukopaks for use in Phase I and II IND programs must comply with GTP. A supplier who does not hold current FDA HCT/P establishment registration and operate under GTP is not compliant for clinical starting material supply.
Good Manufacturing Practice (cGMP): 21 CFR 211 and 600-680
Current Good Manufacturing Practice is the regulatory standard for the manufacture of pharmaceutical drug products and biological products. In the cell therapy context, cGMP governs the manufacturing of the cell therapy investigational product itself and, as programs advance toward Phase III and commercial manufacturing, increasingly governs starting material processing as well.
cGMP requirements are substantially more extensive than GTP requirements. Key distinctions include:
- Process validation. cGMP requires formal process validation demonstrating that the manufacturing process consistently produces a product meeting predetermined specifications. GTP requires SOPs but does not mandate process validation in the same way.
- Facility qualification. cGMP facilities must meet more stringent design and environmental monitoring requirements than GTP, including ISO-classified cleanroom environments for many manufacturing steps.
- Batch record review and release. cGMP batch record review requires a qualified quality unit review of all batch production records before lot release. The documentation requirement is substantially more extensive than GTP lot release documentation.
- Equipment qualification. IQ/OQ/PQ (installation, operational, and performance qualification) for manufacturing equipment is a cGMP expectation; GTP requires appropriate qualification but does not prescribe the IQ/OQ/PQ framework.
- Change control. cGMP change control requirements are more formal than GTP, with documented impact assessments for changes to manufacturing processes, equipment, or facilities.
- Training and personnel qualification. cGMP personnel qualification documentation is more extensive than GTP.
- Stability programs. cGMP requires formal stability programs for licensed products; this expectation is typically less formal at the starting material level but becomes relevant as programs approach BLA submission.
The operational consequence of these distinctions: GMP facility operation costs more than GTP facility operation, requires more personnel, generates more documentation, and produces a more extensive record trail for each lot. These costs are justified by the higher assurance level required for later-stage clinical and commercial manufacturing.
When Each Standard Applies
| Program Phase | Starting Material Standard | Manufactured Product Standard | Notes |
|---|---|---|---|
| Research / preclinical (non-IND) | GTP (if clinical-grade intended) or RUO | Not applicable | RUO material is appropriate for research; if material will be characterized for IND use, GTP-compliant sourcing avoids comparability issues later |
| Phase I IND | GTP minimum | cGMP (21 CFR 1271 + 21 CFR 211 for most cell therapy products) | Phase I has CMC flexibility but starting material must come from registered GTP-compliant supplier |
| Phase II IND | GTP minimum; cGMP preferred for pivotal-ready programs | cGMP | Programs planning Phase III should consider cGMP starting material for Phase II to avoid supplier changes at Phase III |
| Phase III / pivotal IND | cGMP for most programs | cGMP | FDA expects cGMP manufacturing for pivotal trials; starting material under GTP may require bridging justification |
| Commercial / BLA | cGMP | cGMP | Full cGMP supply chain required for licensed products |
The table above reflects the general FDA expectation. Individual program situations vary — FDA may accept GTP starting material for some Phase III programs depending on product type, manufacturing process, and the risk profile of the specific application. The guidance documents and pre-IND meeting discussions with the relevant FDA division will define the specific expectations for your program.
The Transition Problem: When GTP Isn’t Enough Anymore
The most common practical problem with the GTP/cGMP distinction is not misunderstanding the frameworks — it is making starting material supplier selections at Phase I that create friction at Phase III.
The scenario: a Phase I program qualifies a GTP-compliant starting material supplier who does well at small-volume, high-touch Phase I supply. The program advances to Phase II and then Phase III. The sponsor’s CMC team, now focused on the pivotal trial package, realizes that FDA expects cGMP starting material and their current supplier cannot provide it. Qualifying a new cGMP supplier at Phase III requires starting material comparability studies demonstrating that material from the new supplier produces equivalent manufactured cell therapy product as material from the Phase I supplier. That comparability package is not trivial and takes time the Phase III timeline doesn’t have.
The prevention: selecting a starting material supplier at Phase I who can operate under GTP now and cGMP as the program advances, without a supplier change, and whose donor pool enables same-donor continuity from Phase I characterization through Phase III manufacturing.
The Role of Same-Donor Continuity in the GTP-to-GMP Transition
If your program characterizes the manufacturing process using starting material from Donor X during research and Phase I, and then transitions to GMP starting material from a different supplier’s Donor Y for Phase III, you have introduced a comparability question: does manufacturing with Donor Y’s material produce the same cell therapy product as manufacturing with Donor X’s material?
FDA’s comparability framework requires sponsors to demonstrate that manufacturing changes, including starting material source changes, do not adversely affect the identity, quality, purity, safety, or potency of the product. A supplier change from GTP Supplier A to GMP Supplier B mid-program is exactly the kind of change that triggers this comparability obligation.
Same-donor continuity eliminates this problem. If the GTP-compliant characterization work and the GMP Phase III manufacturing both use starting material from the same donor pool, under the same processing infrastructure and quality system, the comparability argument is already made by design. The supplier transition from GTP to GMP is a regulatory framework upgrade within the same supply chain, not a supplier change that introduces new biological variability.
What to Ask Suppliers About Their GTP/GMP Capability
When qualifying a starting material supplier for a program that will advance through multiple clinical phases, the regulatory capability question is not just “are you GTP-compliant?” It is:
- Are all your processing facilities currently FDA-registered and operating under GTP?
- Do you have or are you developing cGMP processing capability for Phase III supply?
- If you currently operate under GTP only, what is your pathway to cGMP for programs that will need it?
- Can you provide starting material from the same donor pool under both GTP and cGMP frameworks, so that same-donor continuity is maintained through the Phase I to Phase III transition?
- Can you provide documented evidence of your quality system — GTP compliance documentation, FDA inspection history, SOPs — for sponsor qualification audit purposes?
Suppliers who cannot clearly answer these questions present a supply chain risk for multi-phase programs. Identifying that risk during initial supplier qualification is significantly better than identifying it at the Phase III IND amendment stage.
OrganaBio’s GTP and GMP Capability
OrganaBio’s Cell Processing Centers operate under GTP as the baseline regulatory standard for all processing operations. For programs requiring cGMP starting material for Phase III and commercial manufacturing, OrganaBio’s CTDMO infrastructure — including the Excellos Labs integration — supports the GMP manufacturing steps that apply as programs advance through clinical phases.
The same donor pool that supports GTP-compliant Phase I starting material is the donor pool from which cGMP collections are drawn as programs scale to Phase III. Same-donor continuity through the GTP-to-cGMP transition is a structural capability, not a custom accommodation.
If you are planning a cell therapy program and want to understand what your starting material regulatory pathway looks like from Phase I through Phase III, OrganaBio’s CTDMO team can work through the specifics with you. Contact us to discuss your program’s regulatory requirements.
Source from OrganaBio
FDA-registered. ISO 7 cGMP. Ships anywhere in the US.
cGMP Manufacturing ServicesCell Processing ServicesFrequently Asked Questions
What is the specific difference between 21 CFR Part 1271 (GTP) and 21 CFR Parts 210/211 (GMP) for cell therapy?
21 CFR Part 1271 governs Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) — requiring FDA registration, donor eligibility determination, required infectious disease testing, and current good tissue practice compliance. It applies to establishments that recover, process, store, or distribute human cells regardless of the downstream use. 21 CFR Parts 210/211 (pharmaceutical GMP) and 21 CFR Part 600 (biologics) apply when the cellular product involves more than minimal manipulation or is intended for non-homologous use — meaning it qualifies as a drug or biologic requiring full GMP manufacturing compliance. Cell therapy products that involve gene modification, ex vivo expansion, or allogeneic use outside the same donor almost always require GMP. Both sets of regulations apply simultaneously to most clinical-stage cell therapy programs — GTP at the starting material collection level, GMP at the manufacturing level.
What does ‘minimal manipulation’ mean under 21 CFR 1271 and how does it determine whether GMP is required?
Minimal manipulation for structural tissue means processing that does not alter the original relevant characteristics of the tissue. For cells, minimal manipulation means processing that does not alter the relevant biological characteristics of the cells — characteristics relating to the cells’ utility for reconstruction, repair, or replacement. Centrifugation, density gradient separation, washing, and freezing are generally considered minimal manipulation. Expansion in culture, genetic modification, activation with cytokines or stimulation protocols, and chemical induction of differentiation are generally considered more than minimal manipulation. When a cell therapy product involves more than minimal manipulation, it falls under the drug/biologic regulatory framework requiring GMP compliance, not GTP alone. The line matters because crossing it changes the regulatory pathway, the required facility infrastructure, and the documentation package required for FDA review.
How does the GTP/GMP interface create documentation gaps during IND review?
The interface between GTP-compliant starting material and GMP-compliant manufacturing is where most documentation gaps appear at IND submission. FDA reviewers expect to see: evidence that the starting material supplier is FDA-registered and operating under 21 CFR 1271; a quality agreement between the supplier and the GMP manufacturer; and traceability documentation linking the donor eligibility determination to the lot COA to the batch record for the manufactured drug product. When the starting material supplier is a GTP-only tissue establishment, they may not produce documentation in the format or with the level of detail a GMP manufacturer needs for their batch record. The receiving GMP manufacturer then has to bridge that gap — often by writing justifications in the batch record or by requesting retrospective documentation from the supplier. Starting with a supplier whose documentation infrastructure was designed for GMP interfaces avoids this problem.
When is GTP compliance alone sufficient for a cell therapy program?
GTP compliance alone is sufficient when the cell therapy product is: (1) used in the same surgical procedure as recovery (autologous, immediate use); (2) meets all four criteria under 21 CFR 1271.10(a) — minimally manipulated, intended for homologous use, not combined with a drug or device that raises new risks, and either autologous or allogeneic between first-degree relatives for non-reproductive use. These scenarios cover a narrow set of clinical applications. For virtually all cell therapy programs in clinical development — CAR-T, TCR therapy, expanded NK cells, allogeneic T cell therapies — more than minimal manipulation is involved, GTP alone is not sufficient, and GMP compliance is required for manufacturing. The GTP compliance of your starting material supplier is necessary but not sufficient for your IND filing.
What does OrganaBio’s dual GTP/GMP compliance mean for programs filing an IND?
OrganaBio operates as a CTDMO under both frameworks simultaneously. At the starting material level, all facilities are FDA-registered under 21 CFR 1271, with donor eligibility determinations, required infectious disease testing, and GTP-compliant SOPs for collection, processing, and release. At the manufacturing level, OrganaBio’s ISO 7 cGMP suites and quality system meet GMP requirements for drug product manufacturing. For a program filing an IND, this dual compliance means: one FDA registration to reference, one quality agreement to negotiate, one audit relationship to maintain, and a supply chain that does not hand off between a GTP establishment and a separate GMP manufacturer. The documentation package — from donor COA through manufacturing batch record — is produced within a single quality system.
